Amphastar Pharma (AMPH): Raising PT to $22 On A $0.22 Beat - Piper Jaffray

August 9, 2016 9:22 AM EDT
Get Alerts AMPH Hot Sheet
Price: $18.45 +1.93%

Rating Summary:
    4 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 19 | New: 11
Trade AMPH Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Piper Jaffray analyst, David Amsellem, reiterated his Overweight rating on shares of Amphastar Pharmaceuticals (NASDAQ: AMPH) after the company reported 2Q16 diluted EPS of $0.23 on revenues of $68M, compared to Street estimates of $0.01 and $62M, respectively. Though enoxaparin continued to face pricing pressure, the rest of the base generic injectibles business benefitted from favorable competitive dynamics on select products, and meaningful volume growth for the naloxone generic.

On the surface AMPH may seem pricey at a 2017 P/E of 23x but there still is potential for significant further value creation as the pipeline bears fruit, driving what should be transformative cash generation over the next several years.

No change to the price target of $22.

For an analyst ratings summary and ratings history on Amphastar Pharmaceuticals click here. For more ratings news on Amphastar Pharmaceuticals click here.

Shares of Amphastar Pharmaceuticals closed at $16.02 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Piper Jaffray

Add Your Comment